CGTX Q2 Loss Narrows as EPS Beats Estimates by $0.02
Cognition Therapeutics reports a smaller-than-expected Q2 loss, with cash reserves totaling $34.8 million as of June 30, 2026. Cognition Therapeutics posted a Q2 GAAP loss per share of $0.04, exceeding expectations by $0.02. The narrower loss reflects improved financial pe